Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus ruxolitinib in myelofibrosis with suboptimal response to ruxolitinib
NCT04551053Phase 3Terminated
- Sponsor
- Incyte
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of parsaclisib in myelofibrosis (MF), sponsored by Incyte. Started May 2021; status: terminated.
02
Drugs
parsaclisib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04551053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551053.